This announcement contains inside information
27 July 2020 07:00 BST
Potential new medicine DS-1062 could redefine treatment
standards in lung, breast and multiple other cancers
澳门葡京网赌游戏与第一三共公司签署了一项新的全球开发和商业化协议, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo专利的滋养细胞表面抗原2 (TROP2)导向抗体药物偶联物(ADC)和治疗多种肿瘤类型的潜在新药.
DS-1062目前正在开发中，用于治疗通常表达细胞表面糖蛋白TROP2的多发性肿瘤. Among them, TROP2 is overexpressed in the majority of non-small cell lung cancers1 and breast cancers,2,3 tumour types that have long been a strategic focus for AstraZeneca. 此次合作反映了澳门葡京网赌游戏将抗体药物偶联物作为一个类别进行投资的战略, 技术的创新性以及与Daiichi Sankyo的成功合作.
Pascal Soriot, Chief Executive Officer, 他说:“澳门葡京赌博游戏看到这种抗体药物结合物在肺癌、乳腺癌和其他通常表达TROP2的癌症中具有巨大的潜力. 澳门葡京赌博游戏很高兴与Daiichi Sankyo进行新的合作，并在成功推出的基础上继续发展 Enhertu to further expand our pipeline and leadership in Oncology. 澳门葡京赌博游戏现在在肿瘤学领域有六个潜在的重磅炸弹，更多的将进入澳门葡京赌博游戏的早期和晚期管道.”
Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo, said: “DS-1062, one of our lead DXd ADCs that will form a pillar of our next mid-term business plan, has the potential to become a best-in-class TROP2 ADC in multiple tumours, including lung and breast cancers. This new strategic collaboration with AstraZeneca, 一家在全球肿瘤业务中拥有丰富经验和重要专业知识的公司, will enable us to deliver DS-1062 to more patients around the world as quickly as possible. As we have done with Enhertu, we will jointly design and implement strategies to maximise the value of DS-1062.”
Using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062旨在选择性地向癌细胞提供化疗，并减少全身暴露. A comprehensive development programme with DS-1062 is planned globally.
Financial considerations
澳门葡京网赌游戏将分期向第一三共支付10亿美元的预付款:交易完成后将支付3.5亿美元, 12个月后3.25亿美元，协议生效后24个月后3.25亿美元.
澳门葡京网赌游戏将额外支付至多10亿美元的有条件金额，用于成功获得监管部门批准，以及至多40亿美元的销售相关里程碑.
The transaction will be accounted for as an intangible asset acquisition, recognised initially at the present value of non-contingent consideration, 任何潜在的未来里程碑付款在确认时资本化为无形资产.
The companies will jointly develop and commercialise DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. 澳门葡京网赌游戏和第一三共将在全球范围内平均分担与DS-1062相关的开发和商业化费用以及利润, 除了日本，第一三共将负责这些费用，并将向澳门葡京网赌游戏支付个位数的专利费. Daiichi Sankyo will record sales in the US, 在欧洲的某些国家以及Daiichi Sankyo有分支机构的其他一些国家. 与澳门葡京网赌游戏分享的来自这些国家的利润将由澳门葡京网赌游戏记录为合作收入. AstraZeneca will record Product Sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within Cost of Sales. Daiichi Sankyo will manufacture and supply DS-1062.
There are no closing conditions to the transaction. The collaboration agreement became effective on 27 July 2020. The transaction does not impact the Company’s financial guidance for 2020.
TROP2
TROP2是一种跨膜糖蛋白，在许多癌症中过表达，包括高达80%的三阴性乳腺癌患者.2,3 在大多数非小细胞肺癌中也发现了高表达的TROP2.1 研究表明，高表达的TROP2与癌细胞的生长和增殖有关.4 TROP2被认为是治疗多种癌症的一个有前途的分子靶点.4
DS-1062
DS-1062 is a TROP2-directed ADC. adc是一种靶向癌症药物，通过连接到单克隆抗体的连接体提供细胞毒性化疗(“有效载荷”)，单克隆抗体与癌细胞上表达的特定靶标结合. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062由人源抗trop2单克隆抗体组成，通过基于四肽的连接体连接到拓扑异构酶I抑制剂负载. DS-1062是一种潜在的新药，尚未在任何国家获得任何适应症的批准. Safety and efficacy have not been established.
Collaboration between AstraZeneca and Daiichi Sankyo in Oncology
In March 2019, 澳门葡京网赌游戏和第一三共进入全球合作，共同开发和商业化 Enhertu (HER2-directed ADC)，除日本外，Daiichi Sankyo在日本拥有专有权.
AstraZeneca in Oncology
澳门葡京网赌游戏在肿瘤学领域有着深厚的传统，并提供快速增长的药物组合 有可能改变患者生活和公司未来的新药. With six new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, 公司致力于将肿瘤作为澳门葡京网赌游戏专注于肺部的关键增长动力, ovarian, breast and blood cancers.
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA损伤反应和抗体药物偶联物-并通过倡导个性化组合的发展, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, 澳门葡京网赌游戏在100多个国家开展业务，其创新药物被全球数百万患者使用. Please visit fitgreenlife.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
1. Inamura K, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017; 8 (17): 28725-28735. http://dx.doi.org/10.18632%2Foncotarget.15647.
2. Zhao W, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018; 40 (2): 759-766. http://doi.org/10.3892/or.2018.6496.
3. Zaman S, et al. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 2019; 12: 1781-1790. http://dx.doi.org/10.2147%2FOTT.S162447.
4. Zeng P, et al. TROP2表达对实体瘤预后的影响:一项系统综述和荟萃分析. Sci Rep. 2016; 6: e33658. http://dx.doi.org/10.1038%2Fsrep33658.
Adrian Kemp
Company Secretary
AstraZeneca PLC